Does Medicare Cover Gynecological Cancer Treatment? 2026 Guide

Yes - Medicare covers gynecological cancer treatment. Surgery, chemotherapy, radiation therapy, targeted drugs, and follow-up imaging are all covered under Parts A, B, and D depending on the setting. For the more than 100,000 American women diagnosed with uterine, ovarian, or cervical cancer each year, most of them Medicare age or approaching it, understanding exactly what Medicare pays for - and what costs remain - is essential planning information.

This guide walks through Medicare coverage for the three most common gynecological cancers: uterine (endometrial), ovarian, and cervical cancer.

Which Gynecological Cancers Does Medicare Cover?

Medicare does not limit coverage by cancer type. Any medically necessary treatment for a gynecological cancer - uterine, ovarian, cervical, vulvar, or vaginal - is covered if ordered by an enrolled Medicare provider.

The three most common types in the Medicare-age population:

  • Uterine cancer (endometrial cancer): The most common gynecological cancer in the US, with roughly 66,000 new cases per year. About 85% of cases are diagnosed after menopause, making this a predominantly Medicare-population disease. The most common type, endometrioid adenocarcinoma, often causes postmenopausal bleeding and is frequently caught at an early, curable stage.
  • Ovarian cancer: About 19,000 new diagnoses per year. More than 60% occur in women 55 and older. Because ovarian cancer rarely causes symptoms until it has spread, roughly 60% of cases are diagnosed at Stage III or IV, when treatment is more intensive.
  • Cervical cancer: About 13,500 new diagnoses per year. Less common in the Medicare population because decades of Pap smear screening catch precancerous cells early. When cervical cancer does develop in older women, it is often in those who had limited access to screening earlier in life.

Part A: Inpatient Hospital Coverage

Medicare Part A covers inpatient hospital stays for gynecological cancer treatment. This includes:

  • Cancer surgery performed as an inpatient admission: hysterectomy for uterine cancer, debulking (cytoreductive) surgery for ovarian cancer, radical hysterectomy for cervical cancer, and pelvic exenteration when disease has spread to surrounding structures
  • Inpatient chemotherapy: if chemotherapy must be given in a hospital rather than an outpatient infusion center
  • Inpatient radiation: less common, but covered when radiation requires inpatient admission
  • Post-surgical recovery: nursing care, physical therapy, wound care, and other medically necessary services during the hospital stay

2026 Part A costs for inpatient surgery:

Inpatient daysYour cost (2026)
Days 1-60$1,736 deductible (one-time per benefit period)
Days 61-90$434/day
Days 91-150$868/day (lifetime reserve days)
Beyond 150 days100% of costs

Most gynecological cancer surgeries involve a 1-5 day hospital stay. With Medigap Plan G, the $1,736 deductible is the only out-of-pocket cost for most admissions.

Part B: Outpatient Coverage

Medicare Part B covers the majority of gynecological cancer care, which increasingly happens in outpatient settings:

Physician and specialist visits: All office visits with your oncologist, gynecologic oncologist, radiation oncologist, and primary care physician are covered at 80% after the Part B deductible ($257 in 2026).

Outpatient surgery: Many hysterectomies and some ovarian procedures can be performed at an outpatient surgery center. Part B covers 80% of the Medicare-approved amount.

Chemotherapy infusions: Drugs administered intravenously at an outpatient infusion center are covered under Part B as “incident to” physician services. This includes the IV carboplatin and paclitaxel (Taxol) regimen used for most ovarian and advanced endometrial cancers. Part B covers 80% after the deductible; you pay 20%.

Radiation therapy: External beam radiation therapy (EBRT) - typically 25-28 treatment sessions over 5-6 weeks - is a Part B outpatient benefit. Brachytherapy (internal radiation delivered by applicator), often used after hysterectomy for uterine cancer, is also covered under Part B.

Diagnostic imaging and labs: CT scans, MRI, PET scans for staging and monitoring, CA-125 blood tests, transvaginal ultrasound, and tumor marker panels are all covered at 80% when ordered by an enrolled provider as medically necessary.

Biopsies and pathology: Endometrial biopsy, dilation and curettage (D&C), colposcopy, loop electrosurgical excision procedure (LEEP), and all associated pathology interpretations are Part B benefits.

Port placement: A surgically placed chemotherapy port (for IV access) is covered as an outpatient procedure.

Part D: Oral Cancer Drugs

Medicare Part D prescription drug plans cover oral chemotherapy and targeted agents used to treat gynecological cancers. Important drugs in this category include:

For ovarian cancer:

  • Olaparib (Lynparza) - PARP inhibitor approved as maintenance therapy after first-line platinum-based chemo in BRCA-mutated ovarian cancer. Taken as oral capsules twice daily. Part D covers it, but as a specialty-tier drug the monthly cost can be $6,000-$10,000 without additional assistance. With the 2025 $2,000 Part D out-of-pocket cap, your maximum annual cost is $2,000 (then Medicare pays 60% of remaining costs).
  • Niraparib (Zejula) - another PARP inhibitor, oral tablet once daily
  • Rucaparib (Rubraca) - third PARP inhibitor option
  • Bevacizumab (Avastin) - actually given IV (Part B), but other targeted agents in this class may be oral

For uterine/endometrial cancer:

  • Medroxyprogesterone acetate (Provera, Depo-Provera) - hormone therapy for low-grade (Grade 1) endometrioid cancer, taken orally; covered under Part D
  • Lenvatinib (Lenvima) - oral targeted therapy approved in combination with pembrolizumab for advanced/recurrent endometrial cancer; Part D specialty tier

For cervical cancer:

  • Oral maintenance agents when applicable

Important: the 2025 Inflation Reduction Act capped out-of-pocket Part D costs at $2,000/year starting in 2025. This means patients taking expensive oral cancer drugs face a maximum of $2,000 in annual drug costs under Part D.

Targeted Therapies and Immunotherapy

Several newer targeted drugs require special consideration:

Pembrolizumab (Keytruda): An immune checkpoint inhibitor given IV every 3-6 weeks. FDA-approved for:

  • Endometrial cancer with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) - in combination with lenvatinib for advanced disease
  • Cervical cancer with PD-L1 expression (combined positive score 1 or above)

Keytruda is administered at an outpatient infusion center and covered under Part B (inpatient) or Part D does not apply - IV drugs at infusion centers are Part B benefits. The list price is roughly $12,000 per infusion; Medicare pays 80% and you owe 20% (capped by Medigap if you have it).

Bevacizumab (Avastin): An anti-angiogenesis drug often added to carboplatin/paclitaxel for ovarian cancer. IV administration, Part B coverage.

HER2-targeted therapy: Some uterine carcinosarcomas and clear-cell endometrial cancers express HER2. Trastuzumab (Herceptin) combinations have shown benefit and are covered under Part B when given IV.

Medicare Coverage for Gynecological Cancer: 2026 Summary Table

TreatmentMedicare partYour cost
Inpatient surgery (hysterectomy, debulking)Part A$1,736 deductible per benefit period
Outpatient surgery (laparoscopic hysterectomy)Part B20% after $257 deductible
IV chemotherapy (carboplatin/paclitaxel)Part B20% per infusion session
External beam radiation (25-28 sessions)Part B20% per session
BrachytherapyPart B20% per treatment
Pembrolizumab / bevacizumab (IV)Part B20% per infusion
PARP inhibitors (oral)Part DCounts toward $2,000 annual cap
Office visits (oncology)Part B20% after deductible
PET/CT/MRI scansPart B20% after deductible
Pap smear (preventive screening)Part B$0 (every 24 months)

Medicare-Covered Screening: Pap Smears and Pelvic Exams

Medicare Part B covers preventive cervical and vaginal cancer screening at no cost:

  • Pap smear: covered every 24 months for average-risk women; every 12 months for women at high risk (prior abnormal Pap, in a high-risk group, or of childbearing age and had an abnormal Pap in the last 3 years)
  • Pelvic exam: covered annually as part of the Welcome to Medicare preventive visit and subsequently as part of the annual wellness visit (AWV)
  • HPV co-test: covered alongside the Pap smear for women 30-65

Women who have already had a hysterectomy for benign reasons are often advised they no longer need Pap smears - but Medicare continues to cover them as a preventive benefit for anyone who wants them.

Medicare Advantage Coverage

Medicare Advantage (Part C) plans must cover everything Original Medicare covers, including all gynecological cancer treatments. However, Advantage plans have their own network requirements and prior authorization rules that can affect care:

Prior authorization: Most Advantage plans require prior authorization (pre-approval) for major surgeries, expensive chemotherapy drugs, and specialty consultations with gynecologic oncologists at academic medical centers.

Network restrictions: HMO plans require you to use in-network oncologists and facilities. If your preferred cancer center - for example, a comprehensive cancer center that specializes in BRCA-related ovarian cancers - is out of network, you may need to appeal, pay out-of-network rates, or switch to a PPO-style Advantage plan.

Specialist access: PPO plans allow out-of-network specialist access at a higher cost share. If you have a rare histology (clear cell, carcinosarcoma, small cell cervical cancer), access to academic specialists at comprehensive cancer centers may be important - a PPO plan preserves that flexibility.

Women diagnosed with or at high risk for gynecological cancer should review their Advantage plan’s formulary and network before starting treatment. For detailed coverage comparisons, see Medicare Advantage HMO vs. PPO plans.

Medigap: Eliminating the 20% Coinsurance

The 20% Part B coinsurance adds up fast with cancer treatment. Five months of carboplatin/paclitaxel infusions, 28 sessions of radiation, 15 oncology visits, and three PET scans can easily total $80,000-$120,000 in Medicare-approved charges. Your 20% share on that is $16,000-$24,000 out of pocket.

Medigap Plan G covers:

  • The Part A deductible ($1,736)
  • All Part A coinsurance during hospitalization
  • 100% of Part B coinsurance (the 20% you would otherwise owe on chemo, radiation, and office visits)

For someone in active gynecological cancer treatment, Medigap Plan G can save tens of thousands of dollars in a single treatment year. If you are newly diagnosed and enrolled in an Advantage plan, talk to a licensed insurance broker about whether switching to Original Medicare plus Medigap Plan G makes financial sense for your treatment plan. You have guaranteed issue rights at certain qualifying events.

Medicare Savings Programs for Lower-Income Beneficiaries

If your income is at or near the federal poverty level, Medicare Savings Programs (MSPs) can:

  • Eliminate your Part B premium ($185/month in 2026)
  • Pay the Part A and Part B deductibles
  • Pay the 20% Part B coinsurance

Combined with Low Income Subsidy (Extra Help) for Part D, lower-income patients may face little or no out-of-pocket cost for cancer treatment. Contact your state Medicaid office or call 1-800-MEDICARE to screen for eligibility.

For details on MSPs, see Medicare Savings Programs.

5 Steps to Maximize Your Medicare Coverage for Gynecological Cancer

  1. Confirm your providers are enrolled in Medicare: Your gynecologic oncologist, radiation oncologist, and the cancer center or hospital must accept Medicare assignment. Call the facility before your first appointment or verify at medicare.gov/care-compare.

  2. Understand your Part A vs. Part B split: Ask your surgeon whether the procedure will be inpatient or outpatient. Outpatient surgery can cost less (no Part A deductible) or more (20% Part B coinsurance vs. flat Part A deductible) depending on your situation and whether you have Medigap.

  3. Check your Part D formulary before starting oral drugs: If you are prescribed a PARP inhibitor or lenvatinib, verify your plan’s formulary tier, prior authorization requirements, and step therapy rules. If the drug is not covered or is on a prohibitively high tier, you have the right to request a formulary exception or switch plans during open enrollment.

  4. Apply for manufacturer patient assistance programs: For expensive targeted drugs like olaparib (Lynparza) or pembrolizumab (Keytruda), the manufacturers offer patient assistance programs. These are separate from Medicare but can fill gaps. Ask your oncology social worker for referrals.

  5. Request a benefits counselor through your cancer center: Most National Cancer Institute (NCI)-designated comprehensive cancer centers have financial counselors or social workers who help Medicare patients navigate coverage, appeal prior authorization denials, and apply for assistance programs.

Frequently Asked Questions

Does Medicare cover a hysterectomy for uterine cancer? Yes. A hysterectomy performed to treat uterine (endometrial) cancer is covered by Medicare Part A if done as an inpatient hospital admission, or Part B if done as an outpatient surgery at a Medicare-certified ambulatory surgery center. You owe the Part A deductible ($1,736 in 2026) or the Part B coinsurance (20%) depending on the setting.

Does Medicare cover chemotherapy for ovarian cancer? Yes. The standard first-line regimen for ovarian cancer - carboplatin plus paclitaxel (Taxol) given IV every 3 weeks for 6 cycles - is covered under Part B as an outpatient infusion benefit. Medicare pays 80% and you pay 20% per session. PARP inhibitor maintenance therapy (oral olaparib, niraparib) is covered under Part D and counts toward the $2,000 annual out-of-pocket cap.

Does Medicare cover BRCA genetic testing for ovarian or breast cancer risk? Medicare covers BRCA1/BRCA2 genetic testing when ordered by a physician who determines it is medically necessary - typically when a woman has a personal history of ovarian cancer or meets hereditary cancer criteria. Coverage is under Part B and the test is usually processed at a clinical laboratory.

Does Medicare cover radiation after a hysterectomy? Yes. Adjuvant pelvic radiation - both external beam radiation and vaginal brachytherapy - after hysterectomy for high-risk uterine cancer is covered under Part B as an outpatient benefit. Standard post-hysterectomy radiation involves about 25 external beam sessions plus 3 brachytherapy sessions.

What is the Medicare age limit for gynecological cancer screening? There is no upper age limit. Medicare covers Pap smears and pelvic exams indefinitely, though the value of continued screening beyond age 65 is debated in clinical guidelines. Talk to your provider about whether continued screening is appropriate for you.

Does Medicare cover Keytruda (pembrolizumab) for gynecological cancer? Yes. Pembrolizumab given IV at an outpatient infusion center is covered under Part B. Medicare pays 80%; you owe 20%. For endometrial cancer, pembrolizumab (with lenvatinib) is approved for MSI-H/dMMR tumors. For cervical cancer, it is approved for PD-L1-positive disease. Prior authorization through Medicare Advantage plans may apply.

Does Medicare cover a second opinion for gynecological cancer? Yes. Medicare Part B covers consultations with another oncologist or gynecologic oncologist for a second opinion. Second opinions are explicitly encouraged for major cancer surgeries. You owe the standard 20% coinsurance.

Are clinical trials covered by Medicare? Yes. Under the Medicare Clinical Trial Policy, Medicare covers routine costs of participating in qualifying clinical trials - including standard drugs given as part of the trial, office visits, and monitoring tests. The experimental drug or device itself is typically provided by the trial sponsor at no cost.

Sources